Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


suck pdf from google scholar
unlimited free pdf from europmc32251768    free
PDF from PMC    free
html from PMC    free
PDF vom PMID32251768  :  Publisher
PDF vom PMID32251768 :   free
PDF vom PMID32251768

suck abstract from ncbi

Nephropedia Template TP Text

Twit Text FOAVip

Twit Text #

English Wikipedia

  • The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro #MMPMID32251768
  • Caly L; Druce JD; Catton MG; Jans DA; Wagstaff KM
  • Antiviral Res 2020[Jun]; 178 (ä): 104787 PMID32251768show ga
  • Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.
  • |*Drug Approval[MESH]
  • |Animals[MESH]
  • |Antiviral Agents/*pharmacology[MESH]
  • |Australia[MESH]
  • |Betacoronavirus/*drug effects/physiology[MESH]
  • |COVID-19[MESH]
  • |Chlorocebus aethiops[MESH]
  • |Coronavirus Infections/drug therapy/*virology[MESH]
  • |Humans[MESH]
  • |Ivermectin/*pharmacology/*therapeutic use[MESH]
  • |Pandemics[MESH]
  • |Pneumonia, Viral/drug therapy/*virology[MESH]
  • |SARS-CoV-2[MESH]
  • |Vero Cells[MESH]
  • |Virus Replication/*drug effects[MESH]

  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    104787 ä.178 2020